Webinars

Click Here to Register Now
Webinar: May 22, 2013
11 a.m. EST – 12 p.m. EST

Time: 11a.m EST - 12p.m. EST

Metabolon Workshops 2010, San Diego, California

An introduction into Metabolomics, Metabolon’s technology for Metabolomics, and two of Metabolon's case studies.

Mike Milburn, Ph.D.
Chief Scientific Officer
Metabolon

The elucidation of the complex molecular and physiological events that characterize the differences between normal cells and cancer cells is under intense investigation both at the research level and in clinical practice. A large number of studies have been reported with DNA, RNA, and protein-based technologies, however, few studies have been performed to characterize cancer at the biochemical level.

It is by gaining this type of mechanistic understanding of a disease that researchers will unlock the keys to discovering new diagnostics. This webcast presentation will provide an overview of a study undertaken to better understand and profile the biochemical changes associated with prostate cancer aggressiveness. Using metabolomics, a global biochemical profiling technology, tissue, urine and plasma samples were analyzed enabling researchers to identify a series of biochemicals (including sarcosine) that are key potential predictors of cancer aggressiveness. (Nature, 12 February 2009)

Attendees will learn about this study as well as how the underlying technology that fueled this discovery is being applied in hundreds of other areas – like diabetes, drug safety research, and even to gain a better of understanding of consumer goods products.

There are many challenges associated with creating a functioning non-targeted metabolomics platform. Current metabolomics methods are often very time consuming and result in many false leads.

Join Annie Evans, Senior R&D Scientist, as she provides insight into non-targeted, analytical metabolomics technology based on a GC/MS and UPLC/MS/MS2 platform. This presentation will discuss how this technology permits rapid project completion, offers broad metabolome coverage, makes high confidence identifications quickly and does so with low process variability and a low false discovery rate. Specific studies will be analyzed in terms of this technology platform and how it addresses many of the challenges limiting the field of metabolomics today.

Using Metabolomics to Profile Effects of Rapamycin on Metabolic Pathways in Human Primary Adipocytes and Hepatocytes

Join Paula Lapinskas, Ph.D. Molecular Toxicology, for this presentation based on work performed while at Signal Pharmaceuticals, LLC (a wholly-owned subsidiary of Celgene Corp.). Analysis includes a discussion about the use of global biochemical profiling and its application in drug action and toxicology.

The study presented highlights a metabolomic approach to understanding the metabolic effects of a drug (rapamycin), an mTOR signal transduction pathway inhibitor used in the treatment of several cancers. The studies were performed on cultured human hepatocytes and adipocytes. The Metabolon global biochemical profiling platform was utilized to identify dose- and time-dependent biochemical changes induced by the drug of interest. Among the metabolic changes that will be discussed are alterations in major energy pathways and insulin resistance in drug-treated cells. These biochemical findings correlate with changes reported in published literature using whole-body approaches, thereby adding validity to the results and additional weight to in vitro assays drug research.

Mike Milburn, Ph.D.
Chief Scientific Officer
Metabolon

Anne Roulston, Ph.D.
Group Leader, Cancer Biology
GeminX

Dana Di Nino, Ph.D.
Senior Research Scientist
Drug Substance Development
Wyeth Biopharma12